› 7vh9

Solution NMR

Solution structure of the chimeric peptide of the first SURP domain of Human SF3A1 and the interacting region of SF1.

Released:
DOI: 10.2210/pdb7vh9/pdb
PDB entry 7vh9 coloured by chain, ensemble of 20 models, front view.
PDB entry 7vh9 coloured by chain, ensemble of 20 models, side view.
PDB entry 7vh9 coloured by chain, ensemble of 20 models, top view.
Source organism: Homo sapiens
Primary publication:
Structural basis for the interaction between the first SURP domain of the SF3A1 subunit in U2 snRNP and the human splicing factor SF1.
Nameki N, Takizawa M, Suzuki T, Tani S, Kobayashi N, Sakamoto T, Muto Y, Kuwasako K
OpenAccess logo Protein Sci 31 e4437 (2022)
PMID: 36173164

Function and Biology Details

Biochemical function:
Biological process:
Cellular component:
  • not assigned
Sequence domains:

Structure analysis Details

Assembly composition:
monomeric (preferred)
Assembly name:
PDBe Complex ID:
PDB-CPX-172292 (preferred)
Entry contents:
1 distinct polypeptide molecule
Macromolecule:
Splicing factor 1; Splicing factor 3A subunit 1 Chain: A
Molecule details ›
Chain: A
Length: 111 amino acids
Theoretical weight: 12.13 KDa
Source organism: Homo sapiens
Expression system: Escherichia coli BL21(DE3)
UniProt:
  • Canonical: Q15459 (Residues: 48-110; Coverage: 8%)
  • Canonical: Q15637 (Residues: 295-327; Coverage: 5%)
Gene names: SAP114, SF1, SF3A1, ZFM1, ZNF162
Sequence domains: Surp module

Ligands and Environments

No bound ligands
No modified residues

Experiments and Validation Details

Entry percentile scores
Chemical shift assignment: 91%
Refinement method: molecular dynamics
Expression system: Escherichia coli BL21(DE3)

Quick links

Citations

2 citation in other articles

Targeted high-throughput mutagenesis of the human spliceosome reveals its in vivo operating principles.
Beusch et al. (2023)
1 more

1 mention without citation

Structural basis for the interaction between the first SURP domain of the SF3A1 subunit in U2 snRNP and the human splicing factor SF1.
Nameki et al. (2022)